Try our Advanced Search for more refined results

Harden Manufacturing Corporation v. Pfizer, Inc. et al

Track this case

Case overview

Case Number:

1:04-cv-10981

Court:

Massachusetts

Nature of Suit:

Other Statutory Actions

Multi Party Litigation:

Class Action

Judge:

Patti B. Saris

Firms

Companies

Sectors & Industries:

  1. May 26, 2015

    Pfizer MDL Plaintiffs Blast Bernstein Liebhard's Fee Bid

    The plaintiffs' steering committee in the multidistrict litigation against Pfizer over its alleged illegal marketing of Neurontin for off-label use told a Massachusetts federal judge Friday that Bernstein Liebhard is seeking more money than it legally deserves.

  2. May 08, 2015

    Pfizer MDL's $91M Atty Fees Misallocated, Firm Says

    Bernstein Liebhard LLP told a Massachusetts federal judge Thursday that the plaintiffs' steering committee in multidistrict litigation accusing Pfizer Inc. of illegally marketing Neurontin for off-label use was unfairly doling out the $91 million in attorneys' fees from the $325 million settlement pot.

  3. November 10, 2014

    Attys' Fee Award Cut To $91M In Pfizer Neurontin MDL

    A Massachusetts federal judge on Monday awarded $91 million to the plaintiffs attorneys in multidistrict litigation accusing Pfizer Inc. of illegally marketing Neurontin for off-label use, saying the $108 million they requested from the $325 million settlement pot was too high.

  4. May 30, 2014

    Pfizer To Pay $325M To End Neurontin Off-Label Suit

    Pfizer Inc. and Warner-Lambert Co. LLC have agreed to pay $325 million to a class of third-party payers who bought the drug Neurontin to settle allegations that they fraudulently marketed the medicine, according to documents filed in Massachusetts federal court on Friday.

  5. April 17, 2014

    Pfizer, Kaiser End Neurontin Off-Label Suit With Fee Deal

    Pfizer Inc. agreed on Wednesday to settle the remaining claims for attorneys' fees in Kaiser Foundation Health Plan Inc.'s suit against the drugmaker in multidistrict litigation over the allegedly deceptive marketing of Neurontin, after the First Circuit determined that the off-label prescriptions harmed Kaiser and others.

  6. May 18, 2011

    Neurontin Judge Won't Certify 3rd-Party Bipolar Class

    A Massachusetts judge in charge of the multidistrict litigation over Pfizer Inc.'s Neurontin refused again Tuesday to certify a subclass of third-party payors accusing the drug giant of fraudulently promoting the epilepsy drug to treat bipolar disorder.

  7. April 20, 2011

    Aetna Loses Bid To Re-Enter Pfizer Off-Label MDL

    A Massachusetts judge on Wednesday refused to reconsider Aetna Inc.'s suit accusing Pfizer Inc. of improperly marketing the epilepsy drug Neurontin in violation of racketeering and competition laws.

  8. April 05, 2011

    166 Plaintiffs Tossed From Neurontin MDL

    In a multidistrict litigation accusing Pfizer Inc. and Warner-Lambert Co. LLC of off-label marketing of epilepsy drug Neurontin, a Massachusetts federal judge on Tuesday dismissed 166 plaintiffs in three lawsuits brought by attorney Levi Boone, citing repeated discovery failures.

  9. December 10, 2010

    Blue Cross, Others Booted In Pfizer Neurontin MDL

    A judge on Friday threw out the bulk of claims brought by consumers, insurers and others in a consolidated class action alleging Pfizer Inc. and Warner-Lambert Co. fraudulently marketed the drug Neurontin for off-label use, ruling that they failed to establish causation.

  10. September 18, 2009

    Pfizer Accuses Expert Of Tainting Doctor Testimony

    Pfizer Inc. is urging a federal court overseeing the multidistrict litigation over its alleged off-label promotion of epilepsy drug Neurontin to issue an order preventing plaintiffs’ counsel and their experts from allegedly trying to tamper with the testimony of plaintiffs’ doctors.

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!